Akums Launches Novel Formulations For Patients With Gastrointestinal Disorders

New Delhi: Akums Drugs & Pharmaceuticals Ltd on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

“Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement.

Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed.

“We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement.

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Related Posts

CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

New Delhi: The pharmacovigilance division of the Central drug regulator has received a total of 1,387 adverse reports, with the highest regarding fixed dose combinations (FDCs), and a total of…

NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

Shimla: The National Green Tribunal (NGT) has issued notice to a pharmaceutical manufacturing unit in Himachal Pradesh over allegations of environmental norm violations, including noise pollution, discharge of untreated or…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

World Record in Robotic Tele-Surgery takes Intercontinental Leap of 20,000 Km

CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

CDSCO receives 1,387 adverse drug reaction reports in nine months of 2025

NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

NGT issues notice to Himachal pharma unit over pollution, water diversion allegations

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports

DGFT Fixes Six New Standard Input Output Norms (SIONs) for Pharmaceutical and Chemical Exports

Nurse, another arrested in ASHA worker’s death at illegal hospital; main accused at large

Nurse, another arrested in ASHA worker’s death at illegal hospital; main accused at large